甲磺酸阿帕替尼和替吉奥治疗晚期胃癌的疗效和预后观察

Clinical efficacy of Apatinib and S1 for the treatment of advanced gastric cancer

目的:比较阿帕替尼和替吉奥治疗晚期胃癌的近期疗效并观察阿帕替尼主要毒副作用及预后因素。方法:将医院经过二线及二线以上治疗失败的60例胃癌患者随机分为对照组及观察组,每组各30例,观察组患者口服阿帕替尼,对照组口服替吉奥,治疗4周。观察两组患者经治疗后的客观缓解率及疾病控制率,同时分析阿帕替尼主要毒副反应及与预后相关因素。结果:两组客观缓解率及疾病控制率相比差异均无统计学意义(P>0.05)。阿帕替尼不良反应主要有高血压、手足综合征、腹泻、白细胞减少及蛋白尿,其中发生高血压及手足综合征不良反应可能有较好疗效。结论:阿帕替尼对二线及二线以上治疗失败的晚期胃癌仍有较好疗效,耐受性好,高血压及手足综合征不良事件可能为其预测预后的指标。

Objective：To compare the curative effect patients after failure of second-line or beyond treatment, between apatinib and S-1 for advanced gastric cancer and observe the toxicity of the apatinib. Methods： Sixty patients with advanced gastric cancer were enrolled in the study, and divided into experiment group and control group. The patients in experiment group were received the apatinib while the control group was treated with S-1 for 4 weeks.Results：There was no difference between the two groups （P〉 0.05）.The most common adverse events were hypertension, hand-foot syndrome, neutropenia diarrhea and proteinuria.The patients had better clinical efficacies who were reported the toxicities of hypertension and hand-foot syndrome.Conclusion：Apatinib was tolerable for the advanced gastric cancer patients after failure of second-line treatment or beyond treatment.The toxicities of hypertension and hand-foot syndrome maybe benefit to the predicting prognosis.